Mesenchymal stem cells lack efficacy in the treatment of experimental autoimmune neuritis despite in vitro inhibition of T-cell proliferation

Marija Sajic; David P.J. Hunt; Woojin Lee; D. Alastair S. Compston; Judith V. Schweimer; Norman A. Gregson; Siddharthan Chandran; Kenneth J. Smith

doi:10.1371/journal.pone.0030708

Mesenchymal stem cells lack efficacy in the treatment of experimental autoimmune neuritis despite in vitro inhibition of T-cell proliferation

Marija Sajic, David P.J. Hunt, Woojin Lee, D. Alastair S. Compston, Judith V. Schweimer, Norman A. Gregson, Siddharthan Chandran, Kenneth J. Smith

School of Psychology and Neuroscience

Research output: Contribution to journal › Article › peer-review

Abstract

Mesenchymal stem cells have been demonstrated to ameliorate experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis, prompting clinical trials in multiple sclerosis which are currently ongoing. An important question is whether this therapeutic effect generalises to other autoimmune neurological diseases. We performed two trials of efficacy of MSCs in experimental autoimmune neuritis (EAN) in Lewis (LEW/Han ^MHsd) rats, a model of human autoimmune inflammatory neuropathies. No differences between the groups were found in clinical, histological or electrophysiological outcome measures. This was despite the ability of mesenchymal stem cells to inhibit proliferation of CD4+ T-cells in vitro. Therefore the efficacy of MSCs observed in autoimmune CNS demyelination models do not necessarily generalise to the treatment of other forms of neurological autoimmunity.

Original language	English
Article number	e30708
Journal	PLoS ONE
Volume	7
Issue number	2
DOIs	https://doi.org/10.1371/journal.pone.0030708
Publication status	Published - 16 Feb 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1371/journal.pone.0030708Licence: CC BY

mesenchymal stem cells
Copyright: © 2012 Sajic et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Final published version, 17.8 MBLicence: CC BY

Cite this

@article{065f362b327c4698b4d830f4364440a0,

title = "Mesenchymal stem cells lack efficacy in the treatment of experimental autoimmune neuritis despite in vitro inhibition of T-cell proliferation",

abstract = "Mesenchymal stem cells have been demonstrated to ameliorate experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis, prompting clinical trials in multiple sclerosis which are currently ongoing. An important question is whether this therapeutic effect generalises to other autoimmune neurological diseases. We performed two trials of efficacy of MSCs in experimental autoimmune neuritis (EAN) in Lewis (LEW/Han MHsd) rats, a model of human autoimmune inflammatory neuropathies. No differences between the groups were found in clinical, histological or electrophysiological outcome measures. This was despite the ability of mesenchymal stem cells to inhibit proliferation of CD4+ T-cells in vitro. Therefore the efficacy of MSCs observed in autoimmune CNS demyelination models do not necessarily generalise to the treatment of other forms of neurological autoimmunity.",

author = "Marija Sajic and Hunt, \{David P.J.\} and Woojin Lee and Compston, \{D. Alastair S.\} and Schweimer, \{Judith V.\} and Gregson, \{Norman A.\} and Siddharthan Chandran and Smith, \{Kenneth J.\}",

note = "DH is funded by a Brain entrance scholarship (Guarantors of Brain) and by the Wellcome Trust. KJS is funded by the Medical Research Council, United Kingdom, the Multiple Sclerosis Society of Great Britian \& Northern Ireland, the European Union (FP6 NeuroproMiSe) and the Brain Research Trust. SC is supported by the National Institute for Health Research Biomedical Research.",

year = "2012",

month = feb,

day = "16",

doi = "10.1371/journal.pone.0030708",

language = "English",

volume = "7",

journal = "PLoS ONE",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "2",

}

TY - JOUR

T1 - Mesenchymal stem cells lack efficacy in the treatment of experimental autoimmune neuritis despite in vitro inhibition of T-cell proliferation

AU - Sajic, Marija

AU - Hunt, David P.J.

AU - Lee, Woojin

AU - Compston, D. Alastair S.

AU - Schweimer, Judith V.

AU - Gregson, Norman A.

AU - Chandran, Siddharthan

AU - Smith, Kenneth J.

N1 - DH is funded by a Brain entrance scholarship (Guarantors of Brain) and by the Wellcome Trust. KJS is funded by the Medical Research Council, United Kingdom, the Multiple Sclerosis Society of Great Britian & Northern Ireland, the European Union (FP6 NeuroproMiSe) and the Brain Research Trust. SC is supported by the National Institute for Health Research Biomedical Research.

PY - 2012/2/16

Y1 - 2012/2/16

N2 - Mesenchymal stem cells have been demonstrated to ameliorate experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis, prompting clinical trials in multiple sclerosis which are currently ongoing. An important question is whether this therapeutic effect generalises to other autoimmune neurological diseases. We performed two trials of efficacy of MSCs in experimental autoimmune neuritis (EAN) in Lewis (LEW/Han MHsd) rats, a model of human autoimmune inflammatory neuropathies. No differences between the groups were found in clinical, histological or electrophysiological outcome measures. This was despite the ability of mesenchymal stem cells to inhibit proliferation of CD4+ T-cells in vitro. Therefore the efficacy of MSCs observed in autoimmune CNS demyelination models do not necessarily generalise to the treatment of other forms of neurological autoimmunity.

AB - Mesenchymal stem cells have been demonstrated to ameliorate experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis, prompting clinical trials in multiple sclerosis which are currently ongoing. An important question is whether this therapeutic effect generalises to other autoimmune neurological diseases. We performed two trials of efficacy of MSCs in experimental autoimmune neuritis (EAN) in Lewis (LEW/Han MHsd) rats, a model of human autoimmune inflammatory neuropathies. No differences between the groups were found in clinical, histological or electrophysiological outcome measures. This was despite the ability of mesenchymal stem cells to inhibit proliferation of CD4+ T-cells in vitro. Therefore the efficacy of MSCs observed in autoimmune CNS demyelination models do not necessarily generalise to the treatment of other forms of neurological autoimmunity.

UR - https://www.scopus.com/pages/publications/84863171061

U2 - 10.1371/journal.pone.0030708

DO - 10.1371/journal.pone.0030708

M3 - Article

C2 - 22359549

AN - SCOPUS:84863171061

SN - 1932-6203

VL - 7

JO - PLoS ONE

JF - PLoS ONE

IS - 2

M1 - e30708

ER -

Mesenchymal stem cells lack efficacy in the treatment of experimental autoimmune neuritis despite in vitro inhibition of T-cell proliferation

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this